Figure 1
Ixazomib inhibits growth and colony formation of esophageal squamous
carcinoma cells. (A), Effect of ixazomib on the viability of breast
cancer cells Kyse150, Kyse510, Kyse520, Eca109 and HECC. Cells were
treated with vehicle or ixazomib (0.1, 1, 10 μM) for 24 h and 48h, the
viability was detected with the CCK-8 kit. (B), ESCC cells were treated
with various concentrations of ixazomib for 24 hours. Cell proliferation
was determined by the CCK-8 assay. IC50 value of ixazomib in ESCC cell
lines was then determined. (C, D), Efficacy of ixazomib on colony
formation of ESCC cells. ESCC cells were treated with ixazomib (0.25,
0.5 μM) for 7days, and then fixed, stained and counted. Values are the
means ± SEM (n = 3). *P < 0.05 or **P < 0.01
indicates significant differences from the vehicle group as assessed by
a two-tailed unpaired Student’s t test.